LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma. Issue 3 (23rd February 2021)

• Record Type: Journal Article
• Authors: Moerdler, Scott; Ewart, Michelle; Friedman, Debra L.; Kelly, Kara; Pei, Qinglin; Peng, Mou; Zang, XingXing; Cole, Peter D.
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 3(2021)
• Page Start: 606
• Page End: 613
• Publication Date: 2021-02-23
• Subjects: Pediatric Hodgkin lymphoma -- LAG-3 -- immune checkpoint -- immunotherapy; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1839651
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: LAG-3, through interaction with a variety of ligands, regulates T cell function via inhibition of T cell proliferation and activation. It has been demonstrated to be overexpressed on tumor infiltrating lymphocytes (TILs) of a variety of cancers with associated poor outcomes. The purpose of this study is to characterize the expression pattern and clinical significance of LAG-3 in pediatric Hodgkin lymphoma (HL). Patient tumor samples from Children's Oncology Group clinical trial AHOD0031 with matched patient outcome data were analyzed for the expression of LAG-3 and PD-L1 using immunohistochemistry. 73/115 patients (63%) demonstrated positive LAG-3 staining. No demographic or survival outcome data were significantly associated with LAG-3 expression. Interestingly, patients with the lowest density of expression were found to have the worst EFS, and those with highest density of expression demonstrated the best EFS. There was a positive statistically significant relationship between presence of LAG-3 and PD-L1 expression. This project is innovative in its characterization of LAG-3 as an immune checkpoint target in pediatric HL.